RedHill Biopharma's partner, Gaelan Medical, has received marketing approval from the United Arab Emirates (UAE) Ministry of Health for Talicia.
The approval makes Talicia the first approved rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori.
Talicia, an innovative fixed-dose oral capsule, which combines two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) called omeprazole. This distinctive formulation has earned approval from the U.S. FDA for effectively treating H. pylori infection in adults.
Talicia stands as the new low-dose rifabutin-centred treatment endorsed for H. pylori infection, distinctly engineered to confront the bacterium's formidable resistance to conventional antibiotics.
H. pylori, a bacterial infection, impacts a majority of the U.S. population, with around two million annual patients undergoing treatment. Globally, over 50 percent of individuals are affected. It remains as the predominant risk contributor to gastric cancer and significantly heightens susceptibility to peptic ulcer disease and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
